Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / OCU410ST
Other

OCU410ST

Tracked across 1 events · 6 articles · First seen Apr 01, 2026 · Last active Apr 01, 2026

Sentiment
70
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 70
Business
Ocugen Completes OCU410ST Dosing Early
Impact: OCU410ST is Ocugen's modifier gene therapy candidate for Stargardt disease, which has successfully completed dosing in its Phase 2/3 clinical trial.
Apr 01, 2026 · 6 articles
ERGEN INTELLIGENCE
Track OCU410ST live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.